Synthesis of β-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase

Archives of Pharmacal Research

Volumn 26, Issue 3, 2003, Pages 197-201

  Taek, Hyeon Kim ^a   Na, Hye Sun ^a   Löffler, Monika ^b  

^a Chonnam National University   (South Korea)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

A 771726; Dihydroorotate dehydrogenase (DHODH); Immunosuppressive activity; Leflunomide; Succinyl acetone; Hydroxy propenamides

Indexed keywords

ANILINE DERIVATIVE; DIHYDROOROTATE DEHYDROGENASE; ENZYME INHIBITOR; HYDROXYBUTYRIC ACID; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; OXIDOREDUCTASE; TERIFLUNOMIDE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; SYNTHESIS;

ANILINE COMPOUNDS; ENZYME INHIBITORS; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS;

EID: 0642347538     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/bf02976829     Document Type: Article

References (18)

1. Bertolini, G., Aquino, M., Biffi, M., dAtri, G., Di Pierro, F., Ferrario, F., Mascagni, P., Somenzi, F., Zaliani, A., and Leoni, F., A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug. J. Med. Chem., 40, 2011-2016 (1997).
2. Borel, J. F., History of cyclosporin A and its significance in immunology. In cyclosporin A, Borel, J. F., Ed.; Elsevier Biochemical Press: Amsterdam, 1982, pp 5-17.
3. Davis, J. P., Cain, G. A., Pitts, W. J., Magolda, R. L., and Copeland, R. A., The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry, 35, 1270-1273 (1996).
4. Elison, G. B. and Hitchings G. H., Azathioprine. Handb. Exp. Pharmacol., 38, 404-425 (1975).
5. Fidler, J. M., Chang, T. G., Bauer, R., Young, J. D., and Vitt, C. R., Suppression of graft-versus-host disease by succinylacetone in a rat allogeneic bone marrow transplantation model. Transplantation, 55, 367-373 (1993).
6. Hess, R. A., Tschudy, D. P., and Blaese, R. M., Immunosuppression by succinylacetone: II. prevention of graft-vs-host disease. J. Immunol., 139, 2845-2849 (1987).
7. Jones, M. E., Pyrimidine nucleotide biosynthesis in animals, genes, enzymes, and regulation of UMP biosynthesis. Annu, Rev. Biochem., 49, 253-256 (1980).
8. Knecht, W., Bergjohann, U., Gonski, S., Kirschbaum, B., and Löffler, M., Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovius vector system, and kinetic investigation of the purified enzyme. Eur. J. Biochem., 240, 292-301 (1996).
9. Knecht, W. and Löffler, M., Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazole and cinchoninic acid derivatives. Biochem. Pharmacol., 56, 1259-1264 (1998).
10. Kuo, E. A., Hambleton, P. T., Kay, D. P., Evans, P. L., Matharu, S. S., Little, E., McDowall, N., Jones, C. B., Hedgecock, C. J. R., Yea, C. M., Chan, A. W. E., Hairsine, P. W., Ager, I. R., Tully, W. R., Williamson, R. A., and Westwood, R., Synthesis, structure-activity relationship, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3- hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl] propenamide and related compounds . J. Med. Chem., 39, 4608-4621 (1996).
11. Lindblad, B., Lindstedt, S., and Steen, G., On the enzyme defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA, 74, 4641-4645 (1977)
12. Papageorgiou, C., Zurini, M., Weber, H.-P., and Borer, X., Leflunomides bioactive metabolite has the minimal structural requirement for the efficient inhibition of human dihydroorotate dehydrogenase. Bioorg. Chem., 25, 233-238 (1997).
13. Perico, N. and Remuzzi, G., Prevention of transplant rejection current treatment guidelines and future developments . Drugs, 54, 533-570 (1997).
14. Sanders, S. and Harisdangkul, V., Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am. J. Med. Sci., 323, 190-193 (2002).
15. Shaw, L. M., Kaplan, B., and Kaufman, D., Toxic effects of immunosuppressive drugs: mechanism and strategies for controlling them. Clin. Chem., 42, 1316-1321 (1996).
16. Skolik, S. A., Palestine, A. G., Blaese, R. M. Nussenblatt, R. B., and Hess, R. A., Treatment of experimental autoimmune uveitis in the rat with systemic succinylacetone. Clin. Immunol. Immunopathol., 49, 63-71 (1988).
17. Tanaka, H., Kuroda, A., Marusawa, H., Hatanaka, H., Kino, T., Goto, T., Hashimoto, M., and Taga, T., Structure of FK506: a novel immunosuppressants isolated from Streptomyces. J. Am. Chem. Soc., 109, 5031-5033 (1987).
18. Tschudy, D. P., Hess, R., Frykholm, B., and Blaese, R. M., Immunosuppressive activity of succinylacetone. J. Lab. Clin. Med., 99, 526-532 (1981).